Terms: = Breast cancer AND PIK3CA, MGC142161, 5290, ENSG00000121879, P42336, MGC142163, p110-alpha, PI3K AND Clinical Outcome
69 results:
1. Conditional generative adversarial network driven radiomic prediction of mutation status based on magnetic resonance imaging of breast cancer.
Huang ZH; Chen L; Sun Y; Liu Q; Hu P
J Transl Med; 2024 Mar; 22(1):226. PubMed ID: 38429796
[TBL] [Abstract] [Full Text] [Related]
2. Two-Dimensional-PAGE Coupled with nLC-MS/MS-Based Identification of Differentially Expressed Proteins and Tumorigenic Pathways in MCF7 breast cancer Cells Transfected for JTB Protein Silencing.
Jayathirtha M; Jayaweera T; Whitham D; Sullivan I; Petre BA; Darie CC; Neagu AN
Molecules; 2023 Nov; 28(22):. PubMed ID: 38005222
[TBL] [Abstract] [Full Text] [Related]
3. The mutational landscape of a US Midwestern breast cancer cohort reveals subtype-specific cancer drivers and prognostic markers.
Vellichirammal NN; Tan YD; Xiao P; Eudy J; Shats O; Kelly D; Desler M; Cowan K; Guda C
Hum Genomics; 2023 Jul; 17(1):64. PubMed ID: 37454130
[TBL] [Abstract] [Full Text] [Related]
4. Genetic Heterogeneity, Tumor Microenvironment and Immunotherapy in Triple-Negative breast cancer.
Kudelova E; Smolar M; Holubekova V; Hornakova A; Dvorska D; Lucansky V; Koklesova L; Kudela E; Kubatka P
Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499265
[TBL] [Abstract] [Full Text] [Related]
5. High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER
Palafox M; Monserrat L; Bellet M; Villacampa G; Gonzalez-Perez A; Oliveira M; Brasó-Maristany F; Ibrahimi N; Kannan S; Mina L; Herrera-Abreu MT; Òdena A; Sánchez-Guixé M; Capelán M; Azaro A; Bruna A; Rodríguez O; Guzmán M; Grueso J; Viaplana C; Hernández J; Su F; Lin K; Clarke RB; Caldas C; Arribas J; Michiels S; García-Sanz A; Turner NC; Prat A; Nuciforo P; Dienstmann R; Verma CS; Lopez-Bigas N; Scaltriti M; Arnedos M; Saura C; Serra V
Nat Commun; 2022 Sep; 13(1):5258. PubMed ID: 36071033
[TBL] [Abstract] [Full Text] [Related]
6. Tumor stromal nicotinamide N-methyltransferase overexpression as a prognostic biomarker for poor clinical outcome in early-stage colorectal cancer.
Ogawa M; Tanaka A; Namba K; Shia J; Wang JY; Roehrl MHA
Sci Rep; 2022 Feb; 12(1):2767. PubMed ID: 35177765
[TBL] [Abstract] [Full Text] [Related]
7. Phase II Study of Taselisib in
Krop IE; Jegede OA; Grilley-Olson JE; Lauring JD; Mitchell EP; Zwiebel JA; Gray RJ; Wang V; McShane LM; Rubinstein LV; Patton D; Williams PM; Hamilton SR; Kono SA; Ford JM; Garcia AA; Sui XD; Siegel RD; Slomovitz BM; Conley BA; Arteaga CL; Harris LN; O'Dwyer PJ; Chen AP; Flaherty KT
JCO Precis Oncol; 2022 Feb; 6():e2100424. PubMed ID: 35138919
[TBL] [Abstract] [Full Text] [Related]
8. Biological and clinical features of triple negative Invasive Lobular Carcinomas of the breast. clinical outcome and actionable molecular alterations.
Conforti F; Pala L; Pagan E; Rocco EG; Bagnardi V; Montagna E; Peruzzotti G; De Pas T; Fumagalli C; Pileggi S; Pesenti C; Marchini S; Corso G; Marchio' C; Sapino A; Graffeo R; Collet L; Aftimos P; Sotiriou C; Piccart M; Gelber RD; Viale G; Colleoni M; Goldhirsch A
Breast; 2021 Oct; 59():94-101. PubMed ID: 34217971
[TBL] [Abstract] [Full Text] [Related]
9. Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial.
Bertucci F; Gonçalves A; Guille A; Adelaïde J; Garnier S; Carbuccia N; Billon E; Finetti P; Sfumato P; Monneur A; Pécheux C; Khran M; Brunelle S; Mescam L; Thomassin-Piana J; Poizat F; Charafe-Jauffret E; Turrini O; Lambaudie E; Provansal M; Extra JM; Madroszyk A; Gilabert M; Sabatier R; Vicier C; Mamessier E; Chabannon C; Pakradouni J; Viens P; André F; Gravis G; Popovici C; Birnbaum D; Chaffanet M
Genome Med; 2021 May; 13(1):87. PubMed ID: 34006291
[TBL] [Abstract] [Full Text] [Related]
10. Serial circulating tumor DNA identification associated with the efficacy and prognosis of neoadjuvant chemotherapy in breast cancer.
Zhou Y; Xu Y; Wang C; Gong Y; Zhang Y; Yao R; Li P; Zhu X; Bai J; Guan Y; Xia X; Yang L; Yi X; Sun Q
Breast Cancer Res Treat; 2021 Aug; 188(3):661-673. PubMed ID: 34003409
[TBL] [Abstract] [Full Text] [Related]
11. The impact of tumor epithelial and microenvironmental heterogeneity on treatment responses in HER2+ breast cancer.
Janiszewska M; Stein S; Metzger Filho O; Eng J; Kingston NL; Harper NW; Rye IH; Alečković M; Trinh A; Murphy KC; Marangoni E; Cristea S; Oakes B; Winer EP; Krop IE; Russnes HG; Spellman PT; Bucher E; Hu Z; Chin K; Gray JW; Michor F; Polyak K
JCI Insight; 2021 Jun; 6(11):. PubMed ID: 33886505
[TBL] [Abstract] [Full Text] [Related]
12. Genomic profile of metastatic breast cancer patient-derived xenografts established using percutaneous biopsy.
Kim S; Shin D; Min A; Kim M; Na D; Lee HB; Ryu HS; Yang Y; Woo GU; Lee KH; Lee DW; Kim TY; Lee C; Im SA; Kim JI
J Transl Med; 2021 Jan; 19(1):7. PubMed ID: 33407601
[TBL] [Abstract] [Full Text] [Related]
13. Therapeutic role of recurrent ESR1-CCDC170 gene fusions in breast cancer endocrine resistance.
Li L; Lin L; Veeraraghavan J; Hu Y; Wang X; Lee S; Tan Y; Schiff R; Wang XS
Breast Cancer Res; 2020 Aug; 22(1):84. PubMed ID: 32771039
[TBL] [Abstract] [Full Text] [Related]
14. A nuclear lncRNA Linc00839 as a Myc target to promote breast cancer chemoresistance via pi3k/AKT signaling pathway.
Chen Q; Shen H; Zhu X; Liu Y; Yang H; Chen H; Xiong S; Chi H; Xu W
Cancer Sci; 2020 Sep; 111(9):3279-3291. PubMed ID: 32619088
[TBL] [Abstract] [Full Text] [Related]
15. B-cell lymphoma 2 family genes show a molecular pattern of spatiotemporal heterogeneity in gynaecologic and breast cancer.
Wang J; Li S; Lin S; Fu S; Qiu L; Ding K; Liang K; Du H
Cell Prolif; 2020 Jun; 53(6):e12826. PubMed ID: 32419250
[TBL] [Abstract] [Full Text] [Related]
16. Integrated molecular profiling of young and elderly patients with triple-negative breast cancer indicates different biological bases and clinical management strategies.
Ma D; Jiang YZ; Xiao Y; Xie MD; Zhao S; Jin X; Xu XE; Shao ZM
Cancer; 2020 Jul; 126(14):3209-3218. PubMed ID: 32383785
[TBL] [Abstract] [Full Text] [Related]
17. Imatinib revives the therapeutic potential of metformin on ewing sarcoma by attenuating tumor hypoxic response and inhibiting convergent signaling pathways.
Nan X; Wang J; Cheng H; Yin Z; Sheng J; Qiu B; Lau CC; Yustein JT; Zhao H; Wong STC
Cancer Lett; 2020 Jan; 469():195-206. PubMed ID: 31672491
[TBL] [Abstract] [Full Text] [Related]
18. BioPATH: A Biomarker Study in Asian Patients with HER2+ Advanced breast cancer Treated with Lapatinib and Other Anti-HER2 Therapy.
Kim SB; Do IG; Tsang J; Kim TY; Yap YS; Cornelio G; Gong G; Paik S; Lee S; Ng TY; Park S; Oh HS; Chiu J; Sohn J; Lee M; Choi YJ; Lee EM; Park KH; Nathaniel C; Ro J
Cancer Res Treat; 2019 Oct; 51(4):1527-1539. PubMed ID: 31163957
[TBL] [Abstract] [Full Text] [Related]
19. GATA1 promotes colorectal cancer cell proliferation, migration and invasion via activating AKT signaling pathway.
Yu J; Liu M; Liu H; Zhou L
Mol Cell Biochem; 2019 Jul; 457(1-2):191-199. PubMed ID: 31069596
[TBL] [Abstract] [Full Text] [Related]
20. A clinical trial of somatic and germline analyses for healthy longevity in a postoperative cancer patient.
Hayashi N; Kuroda Y; Saito T; Tsuruda Y; Niida A; Otsu H; Eguchi H; Masuda T; Suzuki Y; Natsugoe S; Mimori K
Surg Today; 2019 Sep; 49(9):738-747. PubMed ID: 30843125
[TBL] [Abstract] [Full Text] [Related]
[Next]
